Compound research
Sermorelin: Research Overview & Current Status
Sermorelin is a GHRH analog (growth hormone secretagogue). Current research status: approved (non-drug / other indication). Sermorelin acetate was FDA-approved in the U.S. under the brand name Geref for diagnostic and pediatric growth hormone deficiency use, though the original branded product was later discontinued from the U.S. market for commercial reasons; sermorelin is now primarily available via compounding pharmacies and is studied off-label in adult and aging populations.
Overview
Sermorelin is a synthetic 29-amino-acid fragment of human growth hormone-releasing hormone (GHRH), representing the shortest fragment that retains full biological activity of the native hormone. It acts on GHRH receptors in the anterior pituitary to stimulate endogenous growth hormone release, rather than supplying growth hormone directly.
GHRH analog (growth hormone secretagogue)
Research timeline
1980s
GHRH(1-29) fragment identified as the minimal peptide sequence retaining full GH-releasing bioactivity of native GHRH.
Source →1990s
Sermorelin acetate (Geref) approved by FDA for diagnostic testing and treatment of pediatric growth hormone deficiency.
Source →1997
Corpas et al. trial in older men showed short-term GHRH administration could restore GH and IGF-1 levels toward those seen in younger men.
Source →1990s-2000s
Khorram et al. 5-month randomized placebo-controlled trial in adults aged 55-71 reported significant increases in nocturnal GH and serum IGF-1.
Source →2007
PubMed review concluded sermorelin is well-tolerated as a provocative diagnostic test for GH deficiency and modestly effective in promoting growth in some prepubertal children with idiopathic GHD.
Source →2021
Analytical chemistry study developed LC-MS/MS methods to detect sermorelin and related GHRH analogs (tesamorelin, CJC-1295) in urine for anti-doping purposes.
Source →
Active & recent research
Diagnostic use of sermorelin as a provocative test for growth hormone deficiency in children
Evaluating sermorelin injection as a specific, low-false-positive diagnostic stimulation test versus other GH provocation tests
GHRH/sermorelin administration in aging adults
Effect on nocturnal GH pulsatility and serum IGF-1 in age-related GH decline
Detection of GHRH synthetic analogs in sport anti-doping contexts
Identifying metabolites of sermorelin, tesamorelin, and CJC-1295 for analytical detection
Key findings
- A PubMed review reported that intravenous sermorelin (1 mcg/kg) functions as a rapid, relatively specific provocative test for growth hormone deficiency in children, with fewer false positives than some alternative tests.
- A randomized placebo-controlled trial in older adults (Khorram et al.) reported significant increases in nocturnal GH and IGF-1 after GHRH-analog administration in both men and women.
- Preliminary pediatric data cited in a 2007 review suggested continued GH-release and growth-velocity effects with sermorelin treatment tracked up to 36 months, though long-term controlled data remain limited.
- Because sermorelin stimulates endogenous GH release (regulated by feedback via somatostatin) rather than supplying GH directly, researchers have noted it may carry a different overdose/safety profile than exogenous recombinant GH — this is a mechanistic hypothesis discussed in the literature, not a clinical guarantee.
Safety & regulatory notes
Sermorelin acetate (Geref) previously held FDA approval for pediatric GHD diagnosis/treatment; the branded product has since been discontinued in the U.S. market, and current supply is largely through compounding pharmacies, which changes its regulatory status. Reported adverse effects in trials include injection-site reactions, flushing, and headache. Long-term safety data in healthy adult 'anti-aging' or off-label use populations are limited compared to the pediatric diagnostic literature.
We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →
Where it's sold for research
We haven't built a dedicated vendor-availability page for Sermorelin yet. See our full research-peptide vendor rankings →
Sermorelin FAQ
Is sermorelin FDA-approved?+
A sermorelin acetate product (Geref) was previously FDA-approved for pediatric growth hormone deficiency diagnosis and treatment, but the branded product is no longer marketed in the U.S.; current use is largely via compounded formulations, which are regulated differently than an approved drug.
What has research shown about sermorelin in older adults?+
Small trials, such as a 5-month randomized placebo-controlled study by Khorram et al., reported increases in nocturnal GH and IGF-1 levels in adults aged 55-71, but sample sizes were small and this is not an FDA-approved indication.
How does sermorelin differ mechanistically from growth hormone itself?+
Sermorelin is a GHRH receptor agonist that stimulates the pituitary to release the body's own growth hormone, rather than being growth hormone itself; researchers have hypothesized this preserves normal feedback regulation, though this has not been established as a clinical safety guarantee.
Has sermorelin been studied for anti-doping detection?+
Yes — analytical chemistry studies have developed LC-MS/MS methods to detect sermorelin and related GHRH analogs in urine, reflecting its inclusion in sports anti-doping monitoring frameworks.
Sources for this page (4)
Related: all compound research overviews · research radar · full vendor rankings · methodology